BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Saha S, Mara K, Pardi DS, Khanna S. Long-term Safety of Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection. Gastroenterology 2021;160:1961-1969.e3. [PMID: 33444573 DOI: 10.1053/j.gastro.2021.01.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Xu J, Liu C, Shi K, Sun X, Song C, Xu K, Liu Y. Atractyloside-A ameliorates spleen deficiency diarrhea by interfering with TLR4/MyD88/NF-κB signaling activation and regulating intestinal flora homeostasis. International Immunopharmacology 2022;107:108679. [DOI: 10.1016/j.intimp.2022.108679] [Reference Citation Analysis]
2 Saha S, Pardi DS, Khanna S. Reply. Gastroenterology 2021:S0016-5085(21)03162-0. [PMID: 34174246 DOI: 10.1053/j.gastro.2021.06.048] [Reference Citation Analysis]
3 Gweon TG, Lee YJ, Kim KO, Yim SK, Soh JS, Kim SY, Park JJ, Shin SY, Lee TH, Choi CH, Cho YS, Yong D, Chung JW, Lee KJ, Lee OY, Choi MG, Choi M; Gut Microbiota and Therapy Research Group Under the Korean Society of Neurogastroenterology and Motility. Clinical Practice Guidelines for Fecal Microbiota Transplantation in Korea. J Neurogastroenterol Motil 2022;28:28-42. [PMID: 34980687 DOI: 10.5056/jnm21221] [Reference Citation Analysis]
4 Khanna S, Pardi R. Clostridioides difficile infection: curbing a difficult menace. Therap Adv Gastroenterol 2022;15:175628482210899. [DOI: 10.1177/17562848221089906] [Reference Citation Analysis]
5 Qiu P, Ishimoto T, Fu L, Zhang J, Zhang Z, Liu Y. The Gut Microbiota in Inflammatory Bowel Disease. Front Cell Infect Microbiol 2022;12:733992. [DOI: 10.3389/fcimb.2022.733992] [Reference Citation Analysis]
6 Yan S, Yin XM. Gut microbiome in liver pathophysiology and cholestatic liver disease. Liver Res 2021;5:151-63. [PMID: 35355516 DOI: 10.1016/j.livres.2021.08.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Ianiro G, Giambò F, Cammarota G. Residual Gastrointestinal Symptoms after Fecal Microbiota Transplantation for Clostridioides difficile Infection: A Matter of Efficacy Rather Than Safety? Gastroenterology 2021:S0016-5085(21)03079-1. [PMID: 34090885 DOI: 10.1053/j.gastro.2021.06.002] [Reference Citation Analysis]
8 Khanna S. Microbiota restoration for recurrent Clostridioides difficile: Getting one step closer every day! J Intern Med 2021;290:294-309. [PMID: 33856727 DOI: 10.1111/joim.13290] [Reference Citation Analysis]
9 Lu G, Wang W, Li P, Wen Q, Cui B, Zhang F. Washed preparation of faecal microbiota changes the transplantation related safety, quantitative method and delivery. Microb Biotechnol 2022. [PMID: 35576458 DOI: 10.1111/1751-7915.14074] [Reference Citation Analysis]
10 Ghani R, Mullish BH, Roberts LA, Davies FJ, Marchesi JR. The potential utility of fecal (or intestinal) microbiota transplantation in controlling infectious diseases. Gut Microbes 2022;14:2038856. [PMID: 35230889 DOI: 10.1080/19490976.2022.2038856] [Reference Citation Analysis]
11 Lamatsch S, Sittner R, Tacke F, Engelmann C. Novel drug discovery strategies for the treatment of decompensated cirrhosis. Expert Opin Drug Discov 2021;:1-10. [PMID: 34971342 DOI: 10.1080/17460441.2022.2020755] [Reference Citation Analysis]
12 de Stefano MC, Mazzanti B, Vespasiano F, Lombardini L, Cardillo M. The Regulatory Approach for Faecal Microbiota Transplantation as Treatment for Clostridioides difficile Infection in Italy. Antibiotics 2022;11:480. [DOI: 10.3390/antibiotics11040480] [Reference Citation Analysis]
13 Philips CA, Schnabl B, Bajaj JS. Gut microbiome and alcohol-associated liver disease. Journal of Clinical and Experimental Hepatology 2022. [DOI: 10.1016/j.jceh.2021.12.016] [Reference Citation Analysis]
14 Deng M, Wu X, Duan X, Xu J, Yang X, Sheng X, Lou P, Shao C, Lv C, Yu Z. Lactobacillus paracasei L9 improves colitis by expanding butyrate-producing bacteria that inhibit the IL-6/STAT3 signaling pathway. Food Funct 2021;12:10700-13. [PMID: 34605504 DOI: 10.1039/d1fo02077c] [Reference Citation Analysis]
15 Sandhu A, Chopra T. Fecal microbiota transplantation for recurrent Clostridioides difficile, safety, and pitfalls. Therap Adv Gastroenterol 2021;14:17562848211053105. [PMID: 34992678 DOI: 10.1177/17562848211053105] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Yadav D, Khanna S. Safety of fecal microbiota transplantation for Clostridioides difficile infection focusing on pathobionts and SARS-CoV-2. Therap Adv Gastroenterol 2021;14:17562848211009694. [PMID: 33959193 DOI: 10.1177/17562848211009694] [Reference Citation Analysis]
17 Liu Y, Alnababtah K, Cook S, Yu Y. Healthcare providers' perception of faecal microbiota transplantation with clostridium difficile infection and inflammatory bowel disease: a quantitative systematic review. Therap Adv Gastroenterol 2021;14:17562848211042679. [PMID: 34567271 DOI: 10.1177/17562848211042679] [Reference Citation Analysis]
18 Cold F, Svensson CK, Petersen AM, Hansen LH, Helms M. Long-Term Safety Following Faecal Microbiota Transplantation as a Treatment for Recurrent Clostridioides difficile Infection Compared with Patients Treated with a Fixed Bacterial Mixture: Results from a Retrospective Cohort Study. Cells 2022;11:435. [DOI: 10.3390/cells11030435] [Reference Citation Analysis]